However, the lack of significant differences in GLP-1 and PYY responses may reflect blunted incretin sensitivity rather than absolute deficiency or may be due to pharmacological modulation in the T2D group [24]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.